{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T23:53:51Z","timestamp":1770335631436,"version":"3.49.0"},"reference-count":71,"publisher":"Impact Journals, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,1,19]]},"DOI":"10.18632\/oncotarget.23967","type":"journal-article","created":{"date-parts":[[2018,1,5]],"date-time":"2018-01-05T13:56:26Z","timestamp":1515160586000},"page":"6320-6335","source":"Crossref","is-referenced-by-count":16,"title":["Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients"],"prefix":"10.18632","volume":"9","author":[{"given":"Kristian","family":"Taipale","sequence":"first","affiliation":[{"name":"Cancer Gene Therapy Group, University of Helsinki, Faculty of Medicine, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siri","family":"T\u00e4htinen","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, University of Helsinki, Faculty of Medicine, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riikka","family":"Havunen","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, University of Helsinki, Faculty of Medicine, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anniina","family":"Koski","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, University of Helsinki, Faculty of Medicine, Helsinki, Finland"},{"name":"Department of Neurosurgery, HUCH, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilkka","family":"Liikanen","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, University of Helsinki, Faculty of Medicine, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e4ivi","family":"Pakarinen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, HUCH, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riitta","family":"Koivisto-Korander","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, HUCH, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matti","family":"Kankainen","sequence":"additional","affiliation":[{"name":"Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Joensuu","sequence":"additional","affiliation":[{"name":"Docrates Cancer Center, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kanerva","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, University of Helsinki, Faculty of Medicine, Helsinki, Finland"},{"name":"Department of Obstetrics and Gynecology, HUCH, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[{"name":"Cancer Gene Therapy Group, University of Helsinki, Faculty of Medicine, Helsinki, Finland"},{"name":"Docrates Cancer Center, Helsinki, Finland"},{"name":"TILT Biotherapeutics Ltd., Helsinki, Finland"},{"name":"Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2018,1,5]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Curti","year":"2015","journal-title":"J Clin Oncol"},{"key":"2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ebiom.2016.06.046","article-title":"Oncolytic viruses: therapeutics with an identity crisis","volume":"9","author":"Bell","year":"2016","journal-title":"EBioMedicine"},{"key":"3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OV.S66083","article-title":"Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances","volume":"5","author":"Pandha","year":"2016","journal-title":"Oncolytic Virother"},{"key":"4","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Bell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Bell","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"6","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/mt.2016.67","article-title":"Predictive and prognostic clinical variables in cancer patients treated with adenoviral oncolytic immunotherapy","volume":"24","author":"Hemminki","year":"2016","journal-title":"Mol Ther"},{"key":"7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Zloza","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1359-6101(97)00022-1","article-title":"Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF\/MCP-1), chemokines essentially involved in inflammatory and immune reactions","volume":"9","author":"Matsushima","year":"1998","journal-title":"Cytokine Growth Factor Rev"},{"key":"9","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1359-6101(01)00016-8","article-title":"Interleukin-8 and human cancer biology","volume":"12","author":"Xie","year":"2001","journal-title":"Cytokine Growth Factor Rev"},{"key":"10","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1158\/1078-0432.CCR-07-4843","article-title":"The interleukin-8 pathway in cancer","volume":"14","author":"Wilson","year":"2008","journal-title":"Clin Cancer Res"},{"key":"11","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/1078-0432.CCR-13-3203","article-title":"Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins","volume":"20","author":"Sangro","year":"2014","journal-title":"Clin Cancer Res"},{"key":"12","first-page":"3167","article-title":"Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappab","volume":"9","author":"Bar-Eli","year":"2003","journal-title":"Clin Cancer Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/jnci\/djn024","article-title":"Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth","volume":"100","author":"Lutgendorf","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"14","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1378\/chest.126.3.926","article-title":"Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study","volume":"126","author":"Bell","year":"2004","journal-title":"Chest"},{"key":"15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4049\/jimmunol.181.1.669","article-title":"IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis","volume":"181","author":"van de Winkel","year":"2008","journal-title":"J Immunol"},{"key":"16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/jlb.64.1.62","article-title":"Potential involvement of IL-8 in the pathogenesis of human cytomegalovirus infection","volume":"64","author":"Matsushima","year":"1998","journal-title":"J Leukoc Biol"},{"key":"17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cimid.2005.08.003","article-title":"Measles virus infection induces interleukin-8 release in human pulmonary epithelial cells","volume":"28","author":"Kai","year":"2005","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"18","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1128\/JVI.01625-07","article-title":"Viral and host factors in human respiratory syncytial virus pathogenesis","volume":"82","author":"Graham","year":"2008","journal-title":"J Virol"},{"key":"19","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1128\/JVI.78.8.4156-4164.2004","article-title":"Adenovirus type 7 induces interleukin-8 in a lung slice model and requires activation of Erk","volume":"78","author":"Metcalf","year":"2004","journal-title":"J Virol"},{"key":"20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1743-422X-5-17","article-title":"Human adenovirus type 19 infection of corneal cells induces p38 MAPK-dependent interleukin-8 expression","volume":"5","author":"Chodosh","year":"2008","journal-title":"Virol J"},{"key":"21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature14282","article-title":"IL-17-producing gammadelta t cells and neutrophils conspire to promote breast cancer metastasis","volume":"522","author":"de Visser","year":"2015","journal-title":"Nature"},{"key":"22","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.18632\/oncotarget.6430","article-title":"The oncolytic virus dl922-947 reduces IL-8\/CXCL8 and MCP-1\/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma","volume":"7","author":"Portella","year":"2016","journal-title":"Oncotarget"},{"key":"23","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/mt.2016.66","article-title":"Randomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma","volume":"24","author":"Mace","year":"2016","journal-title":"Mol Ther"},{"key":"24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/mt.2015.143","article-title":"Chronic activation of innate immunity correlates with poor prognosis in cancer patients treated with oncolytic adenovirus","volume":"24","author":"Vaha-Koskela","year":"2016","journal-title":"Mol Ther"},{"key":"25","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/mt.2013.51","article-title":"Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients","volume":"21","author":"Oksanen","year":"2013","journal-title":"Mol Ther"},{"key":"26","doi-asserted-by":"crossref","first-page":"e989771","DOI":"10.4161\/2162402X.2014.989771","article-title":"Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy","volume":"4","author":"Hemminki","year":"2015","journal-title":"Oncoimmunology"},{"key":"27","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Hodi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Guse","year":"2010","journal-title":"Cancer Res"},{"key":"29","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Holm","year":"2010","journal-title":"Mol Ther"},{"key":"30","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/mt.2011.113","article-title":"Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus","volume":"19","author":"Joensuu","year":"2011","journal-title":"Mol Ther"},{"key":"31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1189\/jlb.0809532","article-title":"The murine IL-8 homologues KC, MIP-2, and LIX are found in endothelial cytoplasmic granules but not in weibel-palade bodies","volume":"87","author":"Haraldsen","year":"2010","journal-title":"J Leukoc Biol"},{"key":"32","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1525-0016(03)00200-4","article-title":"Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus","volume":"8","author":"Curiel","year":"2003","journal-title":"Mol Ther"},{"key":"33","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2567.1996.d01-784.x","article-title":"Cytokine production of neutrophils is limited to interleukin-8","volume":"89","author":"Rink","year":"1996","journal-title":"Immunology"},{"key":"34","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1089\/hum.2013.123","article-title":"[(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer","volume":"24","author":"Hemminki","year":"2013","journal-title":"Hum Gene Ther"},{"key":"35","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/mt.2011.144","article-title":"Induction of interferon pathways mediatesresistance to oncolytic adenovirus","volume":"19","author":"Marzioni","year":"2011","journal-title":"Mol Ther"},{"key":"36","first-page":"5996","article-title":"Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis","volume":"9","author":"Fan","year":"2003","journal-title":"Clin Cancer Res"},{"key":"37","doi-asserted-by":"crossref","first-page":"7157","DOI":"10.1158\/1078-0432.CCR-04-0812","article-title":"Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival","volume":"10","author":"Dirix","year":"2004","journal-title":"Clin Cancer Res"},{"key":"38","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/CJI.0b013e31819302da","article-title":"IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells","volume":"32","author":"Yang","year":"2009","journal-title":"J Immunother"},{"key":"39","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1124\/jpet.108.143826","article-title":"Chemotherapy-induced CXC-chemokine\/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappab transcription and evasion of apoptosis","volume":"327","author":"Waugh","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"40","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1172\/JCI39397","article-title":"CXCR1 blockade selectively targets human breast cancer stem cellsand in xenografts","volume":"120","author":"Wicha","year":"2010","journal-title":"J Clin Invest"},{"key":"41","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1172\/JCI65416","article-title":"TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer","volume":"123","author":"Arteaga","year":"2013","journal-title":"J Clin Invest"},{"key":"42","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1189\/jlb.72.5.847","article-title":"Multiple control of interleukin-8 gene expression","volume":"72","author":"Kracht","year":"2002","journal-title":"J Leukoc Biol"},{"key":"43","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/mt.2012.137","article-title":"An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol Ther"},{"key":"44","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.2741\/2853","article-title":"The role of chemokines in neutrophil biology","volume":"13","author":"Kobayashi","year":"2008","journal-title":"Front Biosci"},{"key":"45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil (TAN) phenotype by tgf-beta: \u201cN1\u201d versus \u201cN2\u201d tan","volume":"16","author":"Albelda","year":"2009","journal-title":"Cancer Cell"},{"key":"46","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1172\/JCI37223","article-title":"Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model","volume":"120","author":"Weiss","year":"2010","journal-title":"J Clin Invest"},{"key":"47","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1172\/JCI77053","article-title":"Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer","volume":"124","author":"Albelda","year":"2014","journal-title":"J Clin Invest"},{"key":"48","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1084\/jem.192.4.565","article-title":"High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes","volume":"192","author":"Tracey","year":"2000","journal-title":"J Exp Med"},{"key":"49","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1182\/blood-2011-10-386011","article-title":"ALK+ALCLs induce cutaneous, HMGB-1-dependent IL-8\/CXCL8 production by keratinocytes through NF-kappab activation","volume":"119","author":"Meggetto","year":"2012","journal-title":"Blood"},{"key":"50","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/ijc.29539","article-title":"Combined targeting of high-mobility group box-1 and interleukin-8 to control micrometastasis potential in gastric cancer","volume":"137","author":"Lim","year":"2015","journal-title":"Int J Cancer"},{"key":"51","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.4049\/jimmunol.1003187","article-title":"Dysregulation of tim-3-galectin-9 pathway in the cystic fibrosis airways","volume":"186","author":"McElvaney","year":"2011","journal-title":"J Immunol"},{"key":"52","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.4049\/jimmunol.1300711","article-title":"Galectin-9 signaling through tim-3 is involved in neutrophil-mediated gram-negative bacterial killing: an effect abrogated within the cystic fibrosis lung","volume":"192","author":"McElvaney","year":"2014","journal-title":"J Immunol"},{"key":"53","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/2326-6066.CIR-14-0039","article-title":"Tim-3: an emerging target in the cancer immunotherapy landscape","volume":"2","author":"Anderson","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"54","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Kuraguchi","year":"2016","journal-title":"Nat Commun"},{"key":"55","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/gt.2008.3","article-title":"Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition","volume":"15","author":"Yun","year":"2008","journal-title":"Gene Ther"},{"key":"56","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1158\/1078-0432.CCR-13-1471","article-title":"Oncolytic virotherapy trials--letter","volume":"19","author":"Merisalo-Soikkeli","year":"2013","journal-title":"Clin Cancer Res"},{"key":"57","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/mt.2011.230","article-title":"Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol Ther"},{"key":"58","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/mt.2012.115","article-title":"Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol Ther"},{"key":"59","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/ijc.26216","article-title":"Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors","volume":"130","author":"Haavisto","year":"2012","journal-title":"Int J Cancer"},{"key":"60","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/gt.2010.17","article-title":"Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5\/3-Cox2L-D24 in patients with metastatic and refractory solid tumors","volume":"17","author":"Rajecki","year":"2010","journal-title":"Gene Ther"},{"key":"61","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-09-3167","article-title":"Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors","volume":"16","author":"Kangasniemi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"62","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/0008-5472.CAN-11-3001","article-title":"Oncolytic immunotherapy of advanced solid tumors with a cd40l-expressing replicating adenovirus: assessment of safety and immunologic responses in patients","volume":"72","author":"Karioja-Kallio","year":"2012","journal-title":"Cancer Res"},{"key":"63","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and antitumor t-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus","volume":"19","author":"Partanen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"64","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nprot.2011.317","article-title":"Purification and direct transformation of epithelial progenitor cells from primary human prostate","volume":"6","author":"Witte","year":"2011","journal-title":"Nat Protoc"},{"key":"65","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","article-title":"Organoid models of human and mouse ductal pancreatic cancer","volume":"160","author":"Yu","year":"2015","journal-title":"Cell"},{"key":"66","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12868-016-0262-y","article-title":"A non-aggressive, highly efficient, enzymatic method for dissociation of human brain-tumors and brain-tissues to viable single-cells","volume":"17","author":"Grossman","year":"2016","journal-title":"BMC Neurosci"},{"key":"67","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/mt.2015.17","article-title":"T cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses","volume":"23","author":"Vaha-Koskela","year":"2015","journal-title":"Mol Ther"},{"key":"68","doi-asserted-by":"crossref","first-page":"e1022302","DOI":"10.1080\/2162402X.2015.1022302","article-title":"Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific t cell therapy","volume":"4","author":"Lesniak","year":"2015","journal-title":"Oncoimmunology"},{"key":"69","doi-asserted-by":"crossref","first-page":"6734","DOI":"10.4049\/jimmunol.1000225","article-title":"Enrichment of Foxp3+ CD4 regulatory t cells in migrated t cells to IL-6- and IL-8-expressing tumors through predominant induction of cxcr1 by il-6","volume":"185","author":"Nakayama","year":"2010","journal-title":"J Immunol"},{"key":"70","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/icb.2015.42","article-title":"Monocyte:T-cell interaction regulates human T-cell activation through a CD28\/CD46 crosstalk","volume":"93","author":"Astier","year":"2015","journal-title":"Immunol Cell Biol"},{"key":"71","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1084\/jem.20150402","article-title":"Tslp-activated dendritic cells induce human t follicular helper cell differentiation through OX40-ligand","volume":"214","author":"Hori","year":"2017","journal-title":"J Exp Med"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.23967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T11:54:12Z","timestamp":1693396452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.23967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,5]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,1,19]]}},"alternative-id":["23967","29464075"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.23967","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,5]]}}}